Evidence map›Paper›PMID 37450489›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2023

Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.

Annalise Rahman-Filipiak, Corey Bolton, Joshua D Grill, Ayda Rostamzadeh, Nathaniel Chin, Judith Heidebrink, Sarah Getz, Nicole R Fowler, Allyson Rosen, Jennifer Lingler and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Return of research results across the Alzheimer's Disease Research Centers network.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  3. Article
  4. The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Annalise Rahman-FilipiakResearch Program on Cognition & Neuromodulation Based Interventions, University of Michigan, Ann Arbor, Michigan, USA.
Corey BoltonVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Joshua D GrillDepartments of Psychiatry and Human Behavior and Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, California, USA.
Ayda RostamzadehDepartment of Psychiatry and Psychotherapy, Center for Memory Disorders, Faculty of Medicine and University Hospital, University of Cologne, Albertus-Magnus-Platz, Germany.
Nathaniel ChinWisconsin Alzheimer's Disease Research Center, Madison, Wisconsin, USA.
Judith HeidebrinkMichigan Alzheimer's Disease Research Center, University of Michigan, Ann Arbor, Michigan, USA.
Sarah GetzDepartment of Neurology, University of Miami School of Medicine, Miami, Florida, USA.
Nicole R FowlerDivision of General Internal Medicine and Geriatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Allyson RosenPalo Alto Veterans Affairs Medical Center, Palo Alto, California, USA.
Jennifer LinglerDepartment of Health and Community Systems, University of Pittsburgh School of Nursing, Pittsburgh, Pennsylvania, USA.
Ellen WijsmanDivision of Medical Genetics, Department of Medicine and Department of Biostatistics, University of Washington, Seattle, Washington, USA.
Lindsay ClarkDepartment of Medicine, Division of Geriatrics & Gerontology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
Advisory Group on Risk Evidence Education in Dementia (AGREED)

Funding

University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI SUMAN JAYADEV · 2020 to 2026
$29.0M
The Alzheimer's Disease Research Center at the University of California, IrvineP30AG066519 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Elizabeth Head · 2020 to 2026
$27.9M
Research Education ComponentP30AG072931 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DOUGLAS C NOLL · 2021 to 2026
$26.5M
Research Program on Cognition and Neuromodulation Based Interventions (RP-CNBI)R35AG072262 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HAMPSTEAD, BENJAMIN MICHAEL · 2021 to 2025
$4.2M
Decision Making Among Older Adults: the AUTO studyR01AG059613 · NIA · UNIVERSITY OF COLORADO DENVER · PI BETZ, MARIAN ELIZABETH · 2019 to 2023
$3.7M
Small Molecule Discovery for Particulate Guanylyl Cyclase Receptor B EnhancersR01AG056315 · NIA · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C, MALANY, SIOBHAN · 2017 to 2019
$2.0M
Behavioral Change Following Culturally-Informed Biomarker Disclosure in Alzheimer’s DiseaseK23AG070044 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAHMAN-FILIPIAK, ANNALISE · 2021 to 2025
$914k
NIA NIH HHS K23 AG070044NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG072931NIA NIH HHS R01 AG056315NIA NIH HHS R01 AG059613NIA NIH HHS R35 AG072262
6 · The paper itself

Abstract

introductionThe development of biomarkers for Alzheimer's disease (AD) has allowed researchers to increase sample homogeneity and test candidate treatments earlier in the disease. The integration of biomarker "screening" criteria should be met with a parallel implementation of standardized methods to disclose biomarker testing results to research participants; however, the extent to which protocolized disclosure occurs in trials is unknown.

methodsWe reviewed the literature to identify prodromal AD trials published in the past 10 years. From these, we quantified the frequency of biomarker disclosure reporting and the depth of descriptions provided.

resultsOf 30 published trials using positron emission tomography or cerebrospinal fluid-based amyloid positivity as an eligibility criterion, only one mentioned disclosure, with no details on methods. DISCUSSION: Possible reasons for and implications of this information gap are discussed. Recommendations are provided for trialists considering biomarker screening as part of intervention trials focused on prodromal AD. HIGHLIGHTS: Few prodromal Alzheimer's disease (AD) trial papers discuss biomarker disclosure. Disclosure has implications for participants, family members, and trial success. Disclosure must be consistently integrated and reported in prodromal AD trials. Best practice guidelines and training resources for disclosure are needed.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloidAmyloid beta-PeptidesBiomarkersClinical Trials as TopicDisclosureHumansPositron-Emission TomographyProdromal SymptomsAmyloidAmyloid beta-PeptidesBiomarkersamyloidbiomarker disclosuremild cognitive impairmentprodromal Alzheimer's diseaserandomized controlled trials

Identifiers

PMID37450489
PMCPMC10530125

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.